Joon-Tae Kim1, Gregg C Fonarow1, Eric E Smith1, Mathew J Reeves1, Digvijaya D Navalkele1, James C Grotta1, Maria V Grau-Sepulveda1, Adrian F Hernandez1, Eric D Peterson1, Lee H Schwamm1, Jeffrey L Saver2. 1. From Department of Neurology, Chonnam National University Hospital, Gwangju, Korea (J.-T.K.); Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (G.C.F.); Hotchkiss Brain Institute, University of Calgary, Alberta, Canada (E.E.S.); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing (M.J.R.); Department of Neurology, University of Texas Health Science Center, Houston (D.D.N.); Clinical Innovation and Research Institute, Memorial Hermann Hospital, Houston, TX (J.C.G.); Outcome Research and Assessment Group, Duke Clinical Research Institute, Durham, NC (M.V.G.-S., A.F.H., E.D.P.); Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (L.H.S.); and Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (J.L.S.). 2. From Department of Neurology, Chonnam National University Hospital, Gwangju, Korea (J.-T.K.); Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (G.C.F.); Hotchkiss Brain Institute, University of Calgary, Alberta, Canada (E.E.S.); Department of Epidemiology and Biostatistics, Michigan State University, East Lansing (M.J.R.); Department of Neurology, University of Texas Health Science Center, Houston (D.D.N.); Clinical Innovation and Research Institute, Memorial Hermann Hospital, Houston, TX (J.C.G.); Outcome Research and Assessment Group, Duke Clinical Research Institute, Durham, NC (M.V.G.-S., A.F.H., E.D.P.); Department of Neurology, Massachusetts General Hospital, Harvard Medical School, Boston (L.H.S.); and Department of Neurology, David Geffen School of Medicine, University of California, Los Angeles (J.L.S.). jsaver@mednet.ucla.edu.
Abstract
BACKGROUND: Earlier tissue plasminogen activator treatment improves ischemic stroke outcome, but aspects of the time-benefit relationship still not well delineated are: (1) the degree of additional benefit accrued with treatment in the first 60 minutes after onset, and (2) the shape of the time-benefit curve through 4.5 hours. METHODS: We analyzed patients who had acute ischemic stroke treated with intravenous tissue plasminogen activator within 4.5 hours of onset from the Get With The Guidelines-Stroke US national program. Onset-to-treatment time was analyzed as a continuous, potentially nonlinear variable and as a categorical variable comparing patients treated within 60 minutes of onset with later epochs. RESULTS: Among 65 384 tissue plasminogen activator-treated patients, the median onset-to-treatment time was 141 minutes (interquartile range, 110-173) and 878 patients (1.3%) were treated within the first 60 minutes. Treatment within 60 minutes, compared with treatment within 61 to 270 minutes, was associated with increased odds of discharge to home (adjusted odds ratio, 1.25; 95% confidence interval, 1.07-1.45), independent ambulation at discharge (adjusted odds ratio, 1.22; 95% confidence interval, 1.03-1.45), and freedom from disability (modified Rankin Scale 0-1) at discharge (adjusted odds ratio, 1.72; 95% confidence interval, 1.21-2.46), without increased hemorrhagic complications or in-hospital mortality. The pace of decline in benefit of tissue plasminogen activator from onset-to-treatment times of 20 through 270 minutes was mildly nonlinear for discharge to home, with more rapid benefit loss in the first 170 minutes than later, and linear for independent ambulation and in-hospital mortality. CONCLUSIONS: Thrombolysis started within the first 60 minutes after onset is associated with best outcomes for patients with acute ischemic stroke, and benefit declined more rapidly early after onset for the ability to be discharged home. These findings support intensive efforts to organize stroke systems of care to improve the timeliness of thrombolytic therapy in acute ischemic stroke.
BACKGROUND: Earlier tissue plasminogen activator treatment improves ischemic stroke outcome, but aspects of the time-benefit relationship still not well delineated are: (1) the degree of additional benefit accrued with treatment in the first 60 minutes after onset, and (2) the shape of the time-benefit curve through 4.5 hours. METHODS: We analyzed patients who had acute ischemic stroke treated with intravenous tissue plasminogen activator within 4.5 hours of onset from the Get With The Guidelines-Stroke US national program. Onset-to-treatment time was analyzed as a continuous, potentially nonlinear variable and as a categorical variable comparing patients treated within 60 minutes of onset with later epochs. RESULTS: Among 65 384 tissue plasminogen activator-treated patients, the median onset-to-treatment time was 141 minutes (interquartile range, 110-173) and 878 patients (1.3%) were treated within the first 60 minutes. Treatment within 60 minutes, compared with treatment within 61 to 270 minutes, was associated with increased odds of discharge to home (adjusted odds ratio, 1.25; 95% confidence interval, 1.07-1.45), independent ambulation at discharge (adjusted odds ratio, 1.22; 95% confidence interval, 1.03-1.45), and freedom from disability (modified Rankin Scale 0-1) at discharge (adjusted odds ratio, 1.72; 95% confidence interval, 1.21-2.46), without increased hemorrhagic complications or in-hospital mortality. The pace of decline in benefit of tissue plasminogen activator from onset-to-treatment times of 20 through 270 minutes was mildly nonlinear for discharge to home, with more rapid benefit loss in the first 170 minutes than later, and linear for independent ambulation and in-hospital mortality. CONCLUSIONS: Thrombolysis started within the first 60 minutes after onset is associated with best outcomes for patients with acute ischemic stroke, and benefit declined more rapidly early after onset for the ability to be discharged home. These findings support intensive efforts to organize stroke systems of care to improve the timeliness of thrombolytic therapy in acute ischemic stroke.
Authors: Georgios Tsivgoulis; Aristeidis H Katsanos; Pavla Kadlecová; Anna Czlonkowska; Adam Kobayashi; Miroslav Brozman; Viktor Švigelj; Laszlo Csiba; Klara Fekete; Janika Kõrv; Vida Demarin; Aleksandras Vilionskis; Dalius Jatuzis; Yakup Krespi; Chrissoula Liantinioti; Sotirios Giannopoulos; Robert Mikulik Journal: J Neurol Date: 2017-03-18 Impact factor: 4.849
Authors: Christopher T Richards; Baiyang Wang; Eddie Markul; Frank Albarran; Doreen Rottman; Neelum T Aggarwal; Patricia Lindeman; Leslee Stein-Spencer; Joseph M Weber; Kenneth S Pearlman; Katie L Tataris; Jane L Holl; Diego Klabjan; Shyam Prabhakaran Journal: Prehosp Emerg Care Date: 2017-06-29 Impact factor: 3.077
Authors: S Walter; A Ragoschke-Schumm; M Lesmeister; S A Helwig; M Kettner; I Q Grunwald; K Fassbender Journal: Radiologe Date: 2018-11 Impact factor: 0.635
Authors: Martin Ebinger; Bob Siegerink; Alexander Kunz; Matthias Wendt; Joachim E Weber; Eugen Schwabauer; Frederik Geisler; Erik Freitag; Julia Lange; Janina Behrens; Hebun Erdur; Ramanan Ganeshan; Thomas Liman; Jan F Scheitz; Ludwig Schlemm; Peter Harmel; Katja Zieschang; Irina Lorenz-Meyer; Ira Napierkowski; Carolin Waldschmidt; Christian H Nolte; Ulrike Grittner; Edzard Wiener; Georg Bohner; Darius G Nabavi; Ingo Schmehl; Axel Ekkernkamp; Gerhard J Jungehulsing; Bruno-Marcel Mackert; Andreas Hartmann; Jessica L Rohmann; Matthias Endres; Heinrich J Audebert Journal: JAMA Date: 2021-02-02 Impact factor: 56.272
Authors: Silke Walter; Iris Q Grunwald; Stefan A Helwig; Andreas Ragoschke-Schumm; Michael Kettner; Mathias Fousse; Martin Lesmeister; Klaus Fassbender Journal: Curr Atheroscler Rep Date: 2018-08-29 Impact factor: 5.113
Authors: Yaqian Xu; Neal S Parikh; Boshen Jiao; Joshua Z Willey; Amelia K Boehme; Mitchell S V Elkind Journal: Stroke Date: 2019-04 Impact factor: 7.914
Authors: Giorgio Battista Boncoraglio; Michela Ranieri; Anna Bersano; Eugenio A Parati; Cinzia Del Giovane Journal: Cochrane Database Syst Rev Date: 2019-05-05